A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension

Yamada Hiroyuki0 个研究点目标入组 10 人开始时间: 2022年11月22日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•1. Male and female participants who are >= 18 years old.
•2. Signed informed consent prior to participation in the study.
•3. Apparent rHTN at screening (Visit 1) defined as uncontrolled BP with an office msSBP >= 140 mmHg despite treatment with stable (i.e., unchanged for >=4 weeks), optimal or maximally tolerated doses of three or four antihypertensive drugs of different classes, including an ACEI/ARB, a long-acting dihydropyridine CCB, and a thiazide or thiazide-like diuretic. Participant with documented intolerance to any doses of CCBs may be eligible if receiving another class of antihypertensive medication at an optimal or maximally tolerated dose (referred to as triple background antihypertensive therapy). An optimal dose is defined as the highest dose taking in to account participant's documented comorbidities and tolerability per investigator's clinical judgment.
•4. Mean 24hr SBP >=135 mmHg (measured by ABPM) at the end-of Run-in-Visit (Visit 30) on treatment with optimal or maximally tolerated doses of an ACEI/ARB, a long-acting dihydropyridine CCB (or a suitable alternative in case of intolerance per inclusion criterion above), and a thiazide or thiazide-like diuretic.

排除标准

•1. Office msSBP <140 mmHg at Visit 20 or Visit 30 OR office msSBP >=180 mmHg or office msDBP >=110 mmHg at the end-of-run-in visit (Visit 30) OR 24h mean SBP >170 mmHg or 24h mean DBP >105mmHg measured by ABPM at the end of the run-in (Visit 30).
•Subjects with the following blood pressures at the specified time points are not eligible to participate in the study:
•a) Office msSBP <140 mmHg at Visit 20 OR
•b) Office msSBP >=180 mmHg or office msDBP >=110 mmHg at the end-of-run-in visit (Visit 30) OR
•c) 24h mean SBP >170 mmHg or 24h mean DBP >105mmHg measured by ABPM at the end of the run-in (Visit 30).
•2. Known history of secondary hypertension (moderate-to-severe obstructive sleep apnea without receiving CPAP therapy (either face mask or nasal device), renovascular hypertension, primary aldosteronism, pheochromocytoma, Cushing syndrome, aortic coarctation or other cause of secondary hypertension).
•3. Estimated GFR <30 mL/min/1.73m2 using CKD-Epi equation at screening (Visit 1) or at end-of-run-in visit (Visit 30).
•4. Serum potassium >5.0 mmol/L (or equivalent plasma potassium value) at screening or end-of-run-in visit (Visit 30).
•5. Current therapy with a mineralocorticoid receptor antagonist (MRA) or sacubitril/valsartan or received an MRA or sacubitril/valsartan within the 4 weeks prior to screening.
•6. Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma HbA1c >=9%)
•7. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade AV block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) within 6 months of screening according to investigator's judgement.
•8. Chronic non-paroxysmal atrial fibrillation.
•9. Acute myocardial infarction (AMI) or unstable angina, or any history of ischemic or hemorrhagic stroke within 12 months of screening; or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months of screening
•10. History of a renal denervation procedure.
•11. Mid-arm circumference >=44 cm. The cuff should snugly fit on the arm without the margins of cuff overhanging arm musculature.
•12. Patients with history of hospitalisation for hypertensive emergencies characterised by severe hypertension (usually grade 3) associated with funduscopic changes (flame haemorrhages and/or papilloedema), microangiopathy, disseminated intravascular coagulation, encephalopathy, acute aortic dissection, acute myocardial ischaemia, or acute heart failure any time prior to screening or hospitalisation for non-emergent/non-urgent uncontrolled hypertension without target organ damage within 3 months prior to screening.
•13. Receiving more than 4 antihypertensive medications.
•14. Night shift workers.
•15. History of presence of any other disease where the life expectancy is less than 3 years.
•16. History of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin or localized prostate cancer), treated or untreated, within the past 3 years, regardless of whether there is evidence of local recurrence or metastases.
•17. Evidence of hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x the upper limit of normal (ULN), or bilirubin >1.5 mg/dl at Visit 1.
•18. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
•19. History of drug abuse or alcohol dependency.
•20. Lacking the ability to com

研究者

发起方

Yamada Hiroyuki

相似试验

进行中（未招募）

1 期

Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)Eosinophilic Gastritis and/or GastroenteritisMedDRA version: 23.0Level: PTClassification code 10083619Term: Eosinophilic gastritisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: PTClassification code 10017902Term: Gastroenteritis eosinophilicSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2021-000085-14-ESAstraZeneca AB230

进行中（未招募）

1 期

EUCTR2021-000085-14-DEAstraZeneca AB230

进行中（未招募）

1 期

EUCTR2021-000085-14-PLAstraZeneca AB230

已完成

不适用

A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis-M05M05

PER-144-09F. HOFFMANN-LA ROCHE LTD.,24

进行中（未招募）

1 期

Clinical research study of an investigational new drug to treat moderate to severe persistent asthma with type 2 inflammatioModerate to Severe Persistent Asthma with Type 2 Inflammation

EUCTR2021-000583-30-HUSuzhou Connect Biopharmaceuticals Ltd.306